

BSW Formulary Update – May 2022

New additions to BSWformulary

- [Acenocoumarol \(Sinthron®\) 1mg tablet](#) for the treatment and prevention of thromboembolic disease formally added to formulary. Further work required to establish Traffic Light Status and provide information for prescribers. Existing patients should continue to receive prescriptions and monitoring as per their current process.
- [Guanfacine 1mg, 2mg, 3mg and 4mg prolonged release tablets](#) added for use in adult ADHD (off-label). This is in addition to existing formulary indication ([use in children ≥5years](#)). Both indications are currently **RED TLS**; work is ongoing to consider Shared Care positions for guanfacine.

New and Updated Shared Care Agreements and Prescribing Guidance

- **Updated** - [BSW SCA Somatropin for the treatment of growth hormone deficiency in Adults](#) – minor amendments to product information including guidance on obtaining needles for Saizen® Easypod device.
- **Updated** - [BSW SCA Liothyronine \(T3\) for the combination treatment \(T3 + levothyroxine T4\) of hypothyroidism](#) – updated to include information on preferred formulation and cost now capsules are available in 5, 10 and 20 microgram strengths. Capsules are significantly more cost-effective than tablets in primary care.
- **Updated** - [BSW SCA Topical testosterone for low libido in menopause in women on HRT](#) (off-label indication) – updated to reflect new presentation of Testogel® (previously available as 50mg/5g, now comes as 40.5mg/2.5g sachets, one box contains 30 sachets).
- **Updated** - [Guidelines for Dapagliflozin and Empagliflozin in Heart Failure](#) – current guideline updated to include empagliflozin following publication of [NICE TA773](#).
- **New** – [Anticoagulation in NVAF Decision Aid](#) - developed with input from local specialist teams to support switching AF patients to edoxaban from other DOACs in-line with NHSE Investment and Impact Fund indicator (IIF).
- **New** – [Making the most of your food](#) and [Nourishing drinks](#). Two patient information resources developed by BSWCCG dietetic prescribing support team.

What the BSW CCG formulary team are currently working on

- Working with BSW Diabetes Specialist Pharmacist and local teams to:
 - review the BSW insulin formulary for T1 and T2 diabetes
 - produce local guidelines for glucose management in T2 diabetes in adults
 - produce guidance on safe initiation of SGLT2s in T2 diabetes in adults
 - summarise locally approved use of SGLT2s for their various licensed indications
 - summarise pharmacotherapy for chronic kidney disease in primary care
- Working with the BSWCCG Medicines Optimisation Team to review Optimise Profiles in line with BSWformulary. *Please contact bswccg.prescribing@nhs.net in the first instance to clarify TLS status if you have prescribing queries.*

- Working with AWP on guidance and process for the use of SSRIs for first and second-line use for treatment of depression in <18 years of age and on aligning the Traffic Light Status of drugs used for dementia across BSW.

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswccg.formulary@nhs.net